Document is current
Any future updates will be listed below
-
Authors
Rask, Gunilla
Olofsson, Helena
Bauer, Annette
Bodén, Anna
van Brakel, Johannes
Colón-Cervantes, Eugenia
Ehinger, Anna
Kovács, Anikó
Rundgren-Sellei, Åsa
Hartman, Johan
Ågren, Josefin
Darai-Ramqvist, Eva
Andersson, Charlotta
Gustafsson, Christina Kåbjörn
Acs, Balazs https://orcid.org/0000-0002-0972-4633
-
Funding
Funding for this research was provided by:
Svenska Sällskapet för Medicinsk Forskning (PD20-0151)
Karolinska Institute
- License Information
-
More Information
Article History
Received: 17 January 2025
Revised: 8 February 2025
Accepted: 16 February 2025
First Online: 28 February 2025
Declarations
:
: Ethical approval was deemed unnecessary for this study as it exclusively utilized anonymized, de-identified, retrospective data without any direct patient interaction or intervention.
: JH has obtained speaker’s honoraria or advisory board remunerations from Roche, Novartis, Pfizer, EliLilly, MSD, AstraZeneca, and Sakura and has received institutional research support from Roche, MSD, and Novartis. JH is a co-founder and shareholder of Stratipath AB. JÅ are employed by Equalis AB. CKG, CA, and E D-R are all members of Equalis Expert group on pathology/cytology (without remuneration). Other authors have no conflict of interest.
